# Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

> **NCT02352571** · PHASE1 · UNKNOWN · sponsor: **Green Cross Corporation** · enrollment: 72 (estimated)

## Conditions studied

- Neoplasm Metastasis
- Gastric Cancer
- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** GC1118

## Key facts

- **NCT ID:** NCT02352571
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2016-12
- **Final completion:** 2017-06
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2016-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352571, "Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02352571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*